La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Kiniksa Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Kiniksa Pharmaceuticals..

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Azioni, Catena delle Opzioni

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals International PLC

FedEx Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) will release earnings results for the fourth quarter, after the closing <a href="https://www.benzinga.com/quote/FDX/earnings">bell on Tuesday, June 23.</a>
Analysts expect the Memphis, Tennessee-based company to report quarterly earnings at $5.85 per share, up from $5.41 per share in the year-ago period. 
According to data from Benzinga Pro, FedEx projects to report quarterly revenue of $21.81 billion, compared to $22.1 billion a year earlier.
On June 9, FedEx board increased its quarterly dividend from $1.38 to $1.45 per share.
With the recent buzz around FedEx, some investors may be eyeing potential gains from the company's dividends. Currently, FedEx offers an annual dividend yield of 2.53%, which is a quarterly dividend amount of $1.45 per share ($5.80 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $237,024 or around 1,034 shares. For a more modest $100 per month or $1,200 per year, you would need $47,451 or around 207 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($5.80 in this case). So, $6,000 / $5.80 = 1,034 ($500 per month), and $1,200 / $5.80 = 207 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
FDX Price Action: Shares of FedEx rose 2.1% to close at $229.23 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46050117/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

News

Dividends

Markets

Trading Ideas

How To Earn $500 A Month From FedEx Stock Ahead Of Q4 Earnings

Jefferies analyst Maury Raycroft initiates coverage on Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) with a Hold rating and announces Price Target of $3.5.

Price Target

Initiation

Analyst Ratings

CRDF

Jefferies Initiates Coverage On Cardiff Oncology with Hold Rating, Announces Price Target of $3.5

WIIM

ONMD

OneMedNet shares are trading higher after the company entered into private placement agreements with accredited investors raising approximately $3.7 million in gross proceeds.

OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) ("OneMedNet" or the "Company"), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that it has entered into agreements with accredited investors in private placement transactions at $0.42 per share of common stock that resulted in gross proceeds of approximately $3.7 million, before deducting fees and expenses payable by the Company. Certain Company's founders and directors participated in the private placement transactions.
OneMedNet intends to use the proceeds of these private placements for working capital and general corporate purposes. The private placements closed on or about June 19, 2025, and the price per share of common stock sold in these private placements exceeded the minimum price requirement under Nasdaq rules.
During the second quarter of 2025, the Company took additional steps to strengthen its balance sheet and enable it to continue its strategy of adding Bitcoin to the balance sheet:
<ul>
<li>Settling approximately $3.26 million of deferred underwriter fees payable to the underwriter in the Company's business combination transaction.</li>
<li>Settling approximately $1.08 million additional trade payables and other amounts owed by the Company.</li>
<li>Obtaining notices from the Company's noteholders to convert approximately $6.56 million of their principal and interest into Company common stock.</li>
<li>Redeeming for cash the remaining $250,000 outstanding under the Company's original convertible promissory note previously issued to Yorkville Advisors Global in June 2024, which contained certain discounted conversion features.</li>
</ul>
As a result of these actions, the Company settled or converted approximately $11.0 million of the Company's current liabilities, representing a 60% reduction in the Company's total liabilities outstanding as of March 31, 2025.

Offerings

OneMedNet Enters Agreements To Raise $3.7M In Private Placement At $0.42/Share

In a daring bid to underpin its tech future, the UK government has <a href="https://thequantuminsider.com/2025/06/23/uk-commits-500-million-to-quantum-computing-amid-sovereignty-and-security-concerns">committed </a>over £500 million to quantum computing development over the next four years. This historic investment, touted in a report by the Quantum Insider, is Britain&#8217;s most ambitious quantum initiative so far, marking a big step toward technological sovereignty in a fractured era of digital fragmentation.
The Quantum Revolution: Why Now Matters
Quantum computing, based on quantum mechanical principles, is a paradigm shift in computation. Here, unlike classical computers, &nbsp;quantum computers use qubits to solve challenges in cryptography, logistics, molecular modeling, and artificial intelligence, some of which would require todays supercomputers a millennia to solve.
Against the backdrop of mounting cyber threats and increasingly disputed global technology supply chains, quantum computing is no longer a concept, it&#8217;s a strategic imperative. The UK is now joining this competition with an even sharper competitive advantage.
Building Britain&#8217;s Quantum Foundation
The government&#8217;s four-year plan, as outlined in The Quantum Insider, is all about building on three pillars:
• Infrastructure Development – Building local hardware expertise while creating secure, UK-run supply chains.
• Innovation Ecosystem – Funding university research, quantum startups, and commercialization through public-private collaboration.
• Strategic Deployment – Steering quantum to strategic applications like defense, finance, and cryptography where sovereign control is critical.
It serves to accompany the UK&#8217;s National Quantum Strategy, launched in 2023, which pledged £2.5 billion over a decade to support long-term competitiveness in quantum technologies.
Investment Implications: Why It Matters for Markets
For investors and analysts, the move can be a booster for UK technology equities as well as venture capital investments. The quantum computing ecosystem,being in its early growth stage,may now attract greater institutional attention.
Oxford Quantum Circuits, Rigetti UK, and PsiQuantum, among others, may benefit directly from grants, collaborative research, and ecosystem infrastructure. The investment also signals acceleration in complementary industries such as semiconductors, AI, and secure communications.
The potential that quantum algorithms will be able to bypass current encryption techniques within the near future threatens the foundation of blockchain, and thus pressure builds for the creation of quantum-resistant protocols at breakneck speeds.
A Global Arms Race in Quantum
While the UK&#8217;s £500 million commitment is large, it comes within wider geopolitics involving other countries;
United States $1.2B (National Quantum Initiative Act)
European Union €1B (Quantum Flagship Program)
China Estimated $10B+ in government-led investment
United Kingdom £2.5B over 10 years, including new £500M tranche
In contrast to the industrial-scale push of China, the UK policy is centered on selective world leadership in areas of strength: academia, encryption, and scalable innovation startups.
Beyond the Numbers: A Strategic Signal
This isn&#8217;t about new technology, it&#8217;s more about winning national competitiveness in a world where digital infrastructure and cryptography underpin sovereignty. With quantum computing, Britain is not only positioning itself to play, but to set the rules of the game.
For regulators, investors, and tech leaders, the message is clear:
The age of quantum has begun on a global basis. The UK's risk is not just bold it&#8217;s timely.
Disclosure: The author has a BTC investment
&#x2A;&#x2A;
For information on crypto based emerging technology visit <a href="https://cryptoflowzone.com">https://cryptoflowzone.com</a>
&#x2A;&#x2A;

Global

Opinion

Tech

UK's Big Bet On Quantum Future: Bold And Timely

As of June 24, 2025, three stocks in the real estate sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Jones Lang LaSalle Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, JLL named Kelly Howe as CFO, effective July 1. The company's stock jumped around 11% over the past month and has a 52-week high of $288.50.</li>
<li>RSI Value: 70.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>JLL Price Action: Shares of Jones Lang LaSalle gained 3.8% to close at $247.58 on Monday.</li>
<li>Edge Stock Ratings: 55.78 Momentum score with Value at 59.73. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/jll"><img loading="lazy" decoding="async" width="430" height="188" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24052201/image-350.png" alt="" class="wp-image-959433" style="width:327px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24052201/image-350.png 430w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24052201/image-350-300x131.png 300w" sizes="(max-width: 430px) 100vw, 430px" /></a></figure>
<h3 class="wp-block-heading">Hudson Pacific Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>)</h3>
<ul class="wp-block-list">
<li>On June 16, Hudson Pacific Properties announced a $300 million investment from Cohen &amp; Steers to support the company&#8217;s balance sheet recapitalization.. The company's stock gained around 41% over the past month and <a href="https://www.benzinga.com/quote/ HPP">has a 52-week high</a> of $6.28.</li>
<li>RSI Value: 72.6</li>
<li>HPP Price Action: Shares of Hudson Pacific Properties fell 1.1% to close at $2.80 on Monday.</li>
</ul>
<h3 class="wp-block-heading">WP Carey Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>)</h3>
<ul class="wp-block-list">
<li>On June 12, W. P. Carey increased its dividend from 89 cents to 90 cents per share. The company's stock gained around 3% over the past month and has a <a href="https://www.benzinga.com/quote/WPC">52-week high</a> of $66.10.</li>
<li>RSI Value: 71.3</li>
<li>WPC Price Action: Shares of WP Carey gained 1.8% to close at $64.53 on Tuesday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46050117/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Top 3 Real Estate Stocks You May Want To Dump In June

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 1% on Tuesday.
Shares of Kanzhun Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) fell sharply in today's pre-market trading after the company launched dual listing share offer of 30 million shares in Hong Kong and international markets to boost <a href="https://www.benzinga.com/quote/BZ">flexibility and investor base</a>.
Kanzhun shares dipped 2.7% to $17.20 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) shares dipped 62.3% to $3.77 in pre-market trading after gaining 8% on Monday.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) fell 39.2% to $15.06 in pre-market trading. DeFi Development rescheduled release of shareholder letter and business update call to July.</li>
<li>CID HoldCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAIC#NASDAQ">DAIC</a>) dipped 12.8% to $31.80 in pre-market trading.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined 8.8% to $21.62 in pre-market trading after dipping 38% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) dropped 8.2% to $4.69 in pre-market trading.</li>
<li>Ultrapar Participações S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGP#NYSE">UGP</a>) fell 7.4% to $2.86 in pre-market trading.</li>
<li>SS Innovations International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) dipped 5.5% to $5.34 in pre-market trading.</li>
<li>Obsidian Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OBE#NYSE">OBE</a>) fell 4.7% to $5.32 in pre-market trading.</li>
<li>Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) declined 3.3% to $50.22 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Movers

DAIC

DFDV

SSII

UPXI

Kanzhun, DeFi Development And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Loop Capital analyst Anthony Chukumba downgraded the rating for Ollie&#8217;s Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) from Buy to Hold and maintained the price target of $130. Ollie&#8217;s Bargain shares closed at $129.21 on Monday. <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Kate McShane downgraded RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from Neutral to Sell and lowered the price target from $199 to $179. RH shares closed at $186.22 on Monday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Kate McShane downgraded the rating for Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) from Neutral to Sell and lowered the price target from $48 to $46. Advance Auto Parts shares closed at $51.93 on Monday. <a href="https://www.benzinga.com/quote/AAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Kate McShane downgraded Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from Buy to Neutral but raised the price target from $115 to $116. Dollar General shares closed at $114.95 on Monday. <a href="https://www.benzinga.com/quote/DG/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying RH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/RH/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24081924/image-357-1024x575.png" alt="" class="wp-image-959761" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24081924/image-357-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24081924/image-357-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24081924/image-357-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24081924/image-357.png 1153w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

Downgrades

OLLI

This RH Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), adding that the stock &#8220;<a href="https://www.benzinga.com/quote/RBLX/analyst-ratings">goes higher.&#8221;</a>
Supporting his view, Oppenheimer analyst Martin Yang, on June 18, reiterated Roblox with an Outperform rating and raised the price target from $80 to $125.
Cramer said, "Nuclear is coming back. I'm not going to keep anybody out of Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)."
Oklo, on June 17, announced subsidiary Atomic Alchemy commenced site characterization work at a potential location for a commercial radioisotope production facility.
When asked about Lululemon Athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>), he said, &#8220;I am going to punt and say I don't understand LULU. I got it wrong, and let's just move on.&#8221;
On the earnings front, Lululemon, on June 5, reported first-quarter revenue of $2.37 billion, beating the consensus estimate of $2.36 billion, according to Benzinga Pro. The company also cut its FY25 GAAP EPS guidance below estimates.
Cramer said he likes Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) and recommended buying the stock, calling Steve Huffman &#8220;the real deal,&#8221; he added.
As per the recent news, Reddit, on June 16, introduced &#8220;Reddit Insights&#8221; and &#8220;Conversation Summary Add-ons,&#8221; two features designed to help advertisers better understand and participate in Reddit&#8217;s unique community-based environment.
&#8220;I think it's a competitive space. I'm not sure I want to be in it, especially because the stock's up a great deal,&#8221; Cramer said when asked about BlackSky Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NASDAQ">BKSY</a>).
BlackSky Technology, on May 8, reported better-than-expected first-quarter earnings results.
Price Action:
<ul class="wp-block-list">
<li>Oklo shares fell 4.9% to settle at $55.11 on Monday.</li>
<li>Roblox shares gained 1.4% to close at $103.49.</li>
<li>Lululemon fell 0.8% to settle at $225.56 on Monday.</li>
<li>Reddit shares fell 3.6% to close at $134.14.</li>
<li>BlackSky Technology shares jumped 15.8% to settle at $16.47.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/46050117/wall-streets-most-accurate-analysts-give-their-take-on-3-tech-stocks-delivering-high-dividend-yields-7">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Media

BlackSky Technology Inc. Class A Common Stock

BKSY

LULU

OKLO

RBLX

RDDT

Jim Cramer Recommends Buying Roblox, Reddit But Lululemon? 'I Got It Wrong'

Chardan Capital analyst Geulah Livshits maintains Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) with a Buy and maintains $6 price target.

PASG

Chardan Capital Maintains Buy on Passage Bio, Maintains $6 Price Target

<a href="https://www.sec.gov/Archives/edgar/data/1860657/000121390025056913/ea024655701-rw_allaritythera.htm" title="https://www.sec.gov/Archives/edgar/data/1860657/000121390025056913/ea024655701-rw_allaritythera.htm">https://www.sec.gov/Archives/edgar/data/1860657/000121390025056913/ea024655701-rw_allaritythera.htm</a>

ALLR

Allarity Therapeutics Files Form RW, Has Determined Not To Pursue The Public Offering To Which The Registration Statement Relates; The Registration Statement Has Not Been Declared Effective By The Commission And No Securities Have Been Issued Or Sold Under The Registration Statement.

Clearmind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced earlier this month it has engaged a prominent government and political affairs consulting and lobbying firm to support its mission of advancing psychedelic-based treatments.
As psychedelics gain traction in the pharmaceutical industry for their potential to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, Clearmind recognizes the importance of navigating complex regulatory landscapes and fostering greater acceptance among policymakers in the U.S.. The company's partnered with the esteemed firm to support the integration of psychedelic therapies into mainstream healthcare by advocating for informed, science-based regulatory frameworks.

CMND

Clearmind Medicine Engages Government And Political Affairs Consulting And Lobbying Firm To Support Advancing Psychedelic-Based Treatments

Indian multinational IT consulting company&nbsp;HCLTech and&nbsp;Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46069798/hcltech-and-amd-forge-strategic-alliance-to-develop-future-ready-solutions-across-ai-digital-and-c" rel="noreferrer noopener">announced a partnership</a> on Tuesday to accelerate worldwide enterprise digital transformation through advanced AI, digital, and cloud solutions.
By co-investing in innovation labs and training programs, HCLTech and AMD aim to provide enterprises with innovative tools that unlock new business opportunities and enhance operational efficiency.
The joint development centers established through this alliance will serve as testbeds for advanced technologies, conducting proof-of-concept tests to hasten the time-to-market for innovative enterprise tools.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44720974/amd-powers-google-clouds-new-ai-servers-promising-80-boost-in-speed" rel="noreferrer noopener">AMD Powers Google Cloud&#8217;s New AI Servers Promising 80% Boost In Speed</a>
Workforce training and reskilling initiatives will ensure enterprises are well-equipped to navigate the evolving digital landscape.
Dr.&nbsp;Lisa Su, Chair and CEO of AMD, said combining HCLTech&#8217;s expertise in digital transformation with EPYC, Instinct, and Ryzen PRO processors will help provide enterprises with customized, future-ready solutions that maximize the potential of AI, cloud computing, and advanced analytics.
<h2 class="wp-block-heading">Recent Developments</h2>
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) rival AMD has faced challenges in the market, losing over 19% in the last 12 months as it grappled with intense competition from other semiconductor manufacturers, broader macro-economic uncertainties impacting technology spending, and the complexities of semiconductor policies enacted by the U.S. government, particularly regarding exports to certain regions.
Despite these challenges, AMD has continued to innovate. At Computex 2025,&nbsp;AMD showcased <a target="_blank" href="https://www.benzinga.com/tech/25/05/45542185/amd-unveils-powerful-new-ai-gaming-chips-at-computex-to-challenge-nvidia" rel="noreferrer noopener">its latest breakthroughs</a> in&nbsp;high-performance computing&nbsp;with the launch of Radeon RX 9060 XT and Radeon AI PRO R9700 graphics cards and Ryzen Threadripper 9000 Series processors.
Further highlighting AMD&#8217;s ambitions in AI infrastructure, AMD CTO Mark Papermaster <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46034864/this-could-be-amds-biggest-ai-win-mi400-chips-may-power-stargate" rel="noreferrer noopener">had hinted that</a> AMD MI400 chips could be part of the $500 billion Stargate Project.
The Stargate Project is a massive initiative, spearheaded by OpenAI in partnership with companies like SoftBank (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) and Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), to build a network of state-of-the-art AI data centers in the United States, signifying a colossal investment in AI infrastructure.
Bank of America Securities (BofA) analyst&nbsp;Vivek Arya highlighted &#8220;multiple growth cylinders&#8221; for AMD, indicating diverse areas of potential growth, and noted continued market share gains in PC/server CPU against its long-standing competitor Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>).
Price Action: AMD stock is trading higher by 2.33% to $132.60 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46071407/gopro-just-made-your-phone-a-powerful-editing-studio" target="_blank" rel="noreferrer noopener">GoPro Just Made Your Phone A Powerful Editing Studio</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

INTC

NVDA

ORCL

SFTBY

HCLTech, AMD Partner To Power Next-Gen Enterprise AI And Cloud Adoption

D. Boral Capital analyst Jesse Sobelson maintains EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) with a Buy and maintains $2 price target.

EONR

D. Boral Capital Maintains Buy on EON Resources, Maintains $2 Price Target

CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) ("CURRENC" or the "Company"), a fintech pioneer empowering financial institutions worldwide with artificial intelligence (AI) solutions, today announced that it has entered a strategic partnership with Galaxy Payroll Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLXG#NASDAQ">GLXG</a>) ("Galaxy Group") to jointly create innovative AI-powered human resources solutions for CURRENC's "AI Staff for Hire" platform. Leveraging Galaxy Group's deep industry expertise and CURRENC's advanced AI technology, the parties will develop two new modules, AI HR Manager and AI Recruitment Manager, extending CURRENC's reach to the HR sector.

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

GLXG

CURRENC Group Partners With Galaxy Payroll Group To Jointly Create AI-Powered Human Resources Solutions For CURRENC's "AI Staff For Hire" Platform

Strategic agreement brings innovative electrotherapy and orthotic solutions to America's veterans, active duty and DoD personnel
ALEXANDRIA, Va., June 24, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455131-1&amp;h=3455018313&amp;u=https%3A%2F%2Fwww.mellingmedical.com%2F&amp;a=Melling">Melling</a><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455131-1&amp;h=282231282&amp;u=https%3A%2F%2Fwww.mellingmedical.com%2F&amp;a=Medical">Medical</a>&nbsp;announced today a new strategic relationship with Zynex Medical, an industry pioneer in non-invasive medical devices for pain management and rehabilitation. The collaboration leverages MellingMedical's status as an SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to bring Zynex's innovative pain management solutions to federal healthcare providers serving America's military personnel, DoD and veterans.

Biotech

General

ZYXI

MellingMedical Teams Up With Zynex Medical To Expand Access To Non-Invasive Pain Management Solutions Across Federal Healthcare System

D. Boral Capital analyst Jason Kolbert maintains Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) with a Buy and maintains $16 price target.

BMEA

D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $16 Price Target

NXXT

NextNRG 2025 Revenue $6.6M, Up 148% YoY

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profile
Ethics approval and Phase 1 clinical trial start in prostate cancer anticipated in 2H 2025
SYDNEY and BUNDOORA, Australia, June 24, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RADX#NASDAQ">RADX</a>, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced the signing of a supply agreement with Cyclotek to radiolabel RAD 402 with Terbium-161 (161Tb) in Australia, which supports the initiation of a Phase 1 clinical trial. RAD 402 is an anti-Kallikrein Related Peptidase 3 (KLK3) monoclonal antibody radiotherapeutic labelled with the radionuclide 161Tb for treatment of prostate cancer.
RAD 402 has been designed to target KLK3, which is highly expressed in the prostate, with very limited/no expression in other tissues and organs. Compared to 177Lu, 161Tb emits additional Auger and conversion electrons alongside its β-radiation, which can lead to potentially improved antitumoral therapeutic efficacy. 161Tb-RAD 402 is the first company-sponsored Phase I trial in prostate cancer using 161Tb.
Under the agreement, Cyclotek will produce and provide doses of 161Tb-labeled RAD 402 to support Radiopharm's upcoming Phase 1 clinical trial in prostate cancer in Australia. The Phase 1 trial is anticipated to start in the second half of 2025.

RADX

Radiopharm Theranostics Signs Supply Agreement With Cyclotek To Radiolabel RAD 402 With Terbium-161 In Australia, Which Supports Initiation Of Phase 1 Clinical Trial

NAOV

NanoVibronix Announces A Regional Hospital Signed Agreement to Acquire Two ENvue Navigation Systems

Press Releases

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Health Care

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Comments

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals (KNSA) Opzioni

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO